This page contains recent news articles, when available, and an overview of but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Background information on

Updates in the Management of Myelodysplastic Syndromes  -  24 Mar 2008
Cancer Consultants,The myelodysplastic syndromes (MDS) are a collection of clonally-derived hematopoietic disorders typified by peripheral blood cytopenias,

Daily Cancer News  -  24 Mar 2008
Cancer Consultants,...has been effective in treating thrombocytopenia associated with immune (idiopathic) thrombocytopenia purpura (ITP) and myelodysplastic syndromes (MDS).

Bothell's Seattle Genetics pitches drug combo  -  Mar 21, 2008
HeraldNet,It makes sense to test the drug against myelodysplastic syndromes, because it is related to the leukemia already being targeted by Seattle Genetics,

Alexion Completes Enrollment In AEGIS Registration Study Of ...  -  Mar 22, 2008
Medical News Today (press release),...(4,6) PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndromes

Haematology moot begins today  -  Mar 13, 2008
Daily Times,...and bone marrow failure syndromes (aplastic anemia), congenital bone marrow syndromes and current management strategies of myelodysplastic syndromes).

... Go to the Article  -  Mar 3, 2008
CancerWiseMyelodysplastic syndromes, which are often lethal, are a group of conditions that cause insufficient production of blood cells.

Seattle Genetics initiates MDS combination therapy trial  -  Mar 21, 2008
Trading Markets (press release),...antitumor activity of SGN-33 in combination with the oral cancer drug Revlimid for patients with intermediate and advanced myelodysplastic syndromes.

Seattle Genetics Initiates SGN-33 Clinical Trial in Combination ...  -  Mar 20, 2008
Earthtimes,...in combination with the oral cancer drug Revlimid® (lenalidomide) for patients with intermediate and advanced myelodysplastic syndromes (MDS).

Technology Briefing  -  Mar 20, 2008
Seattle Post Intelligencer...of Seattle Genetics' SGN-33 therapy when used in combination with Celgene's oral cancer drug, Revlimid, in 30 patients with myelodysplastic syndromes.

Leukemia & Lymphoma Society offering telephone support group  -  Mar 18, 2008
Evening Observer,...by telephone for adult patients who have been diagnosed with leukemia, myelodysplastic syndromes (MDS), Hodgkin or non-Hodgkin lymphoma, or myeloma.

Study shows way to predict lung cancer recurrence  -  Mar 12, 2008
Scientific AmericanSome drugs can home in on these changes however -- notably drugs used to treat myelodysplastic syndromes, sometimes known as pre-leukemia.

Benzene Related Diseases: Leukemia  -  Mar 1, 2008
TamilStar.com,Some of these other diseases include: Myelodysplastic syndromes: also called 'pre-leukemia', this is a collection of diseases resulting in diminished blood

Novel Mechanism Found That May Boost Impaired Function Of Leukemia ...  -  Feb 29, 2008
Science Daily (press release)...that target protein methylation, although two drugs that target DNA methylation are FDA approved for treating patients with myelodysplastic syndromes.

Celgene CEO lays out firm's game plan  -  Mar 14, 2008
The Star-Ledger - NJ.com,Pharmion's most promising drug in the short term is Vidaza, a treatment for myelodysplastic syndromes, or MDS, which helps round out Celgene's blood cancer

Celgene Closer to Closing Pharmion Deal  -  Mar 13, 2008
FDA news (subscription),Pharmion had 2007 sales of $267.3 million, mostly from Vidaza (azacitidine for injection), a treatment for higher-risk myelodysplastic syndromes.

FDA Committee Recommends Approval for Amgen’s Platelet Generator  -  Mar 13, 2008
FDA news (subscription),The drug also may increase the proportion of blast cells in the peripheral blood of some patients with myelodysplastic syndromes. The committee agreed that

Ortho Biotech Statement on US Food and Drug Administration ...  -  Mar 13, 2008
PR Newswire (press release),...known history of a seizure disorder or underlying hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders).

BUYINS.NET: GNLB, ORBC, SGLP, CCNI, ILNS, SWVC Have Also Been ...  -  Feb 26, 2008
Trading Markets (press release),Huntington's disease, diabetes, stroke, myelodysplastic syndromes, motor neuron disease (ALS and Lou Gehrig's disease), and radiation injury.

Author : The Leukemia & Lymphoma Society  -  Feb 26, 2008
Earthtimes,...non- Hodgkin lymphoma, chronic lymphocytic leukemia, waldenstrom macroglobulinemia, acute myelogenous leukemia, myeloma and myelodysplastic syndromes.

Lenalidomide Reduces Transfusion Need for Some Myelodysplastic ...  -  20 Feb 2008
Cancerpage.com,...for transfusions in certain transfusion-dependent patients with myelodysplastic syndromes (MDS) who lack the deletion 5q karyotypic abnormality.

Myelodysplastic Syndromes - First Approvals Spur Some Interest in ...  -  20 Feb 2008
Business Wire (press release),Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36769 across the seven major

Lenalidomide (REVLIMID ® ) Receives Orphan Drug Status in Japan ...  -  Feb 19, 2008
Business Wire (press release),Myelodysplastic syndromes are a group of hematologic malignancies that affect approximately 300000 people worldwide. Myelodysplastic syndromes occur when

EMEA Accepts for Review Vidaza(R) Marketing Authorization ...  -  Feb 7, 2008
CNNMoney.comIn May 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza,

Celgene Reports on REVLIMID(R) (Lenalidomide) Global Regulatory ...  -  Jan 24, 2008
WELT ONLINE,About Myelodysplastic Syndromes Myelodysplastic syndromes (MDS) are a group of hematologic malignancies that affect approximately 300000 people worldwide.

Pharmion calls shareholder meeting for Celgene vote  -  Feb 4, 2008
Bizjournals.com,Celgene plans to make Pharmion a wholly-owned subsidiary and, in doing so, pickup the right to distribute the treatments for myelodysplastic syndromes

Questions and Answers on Recommendation for the Refusal of the ...  -  Jan 24, 2008
PharmaLive.com (press release),Lenalidomide Celgene Europe was expected to be used to treat anaemia (low red blood cell counts) caused by myelodysplastic syndromes, a group of conditions

New Oral Medication Gives Hope to Patients with Blood Cancer  -  Jan 24, 2008
Canada NewsWire (press release),REVLIMID(R) Receives Health Canada Approval for the Treatment of Deletion 5q Myelodysplastic Syndromes OAKVILLE, ON, Jan. 24 /CNW/ - Celgene announced today

Celgene reports global regulatory developments on Revlimid  -  Jan 25, 2008
Trading Markets (press release),...results of regulatory actions regarding Revlimid in Australia in multiple myeloma, and in Canada and the EU in deletion 5q myelodysplastic syndromes.

Pharmion Corporation Announces 2007 Operating Results  -  Feb 19, 2008
MSN Money...connection with the release of overall survival data from the Vidaza Phase 3 study for the treatment of higher risk myelodysplastic syndromes patients.

Pharma Blog Watch  -  Feb 1, 2008
FDA news (subscription),The drug recently was approved for myelodysplastic syndromes in Australia and Canada and for multiple myleoma in Australia. It looks as if the company could

Last Call: Celgene Falls on EC Opinion  -  Jan 24, 2008
Forbes,He expects about $120 million in sales for myelodysplastic syndromes in Europe, out of a total of $1.26 billion in 2008 revenue.

Celgene gets orphan drug status in Japan  -  Feb 19, 2008
Forbes,Lenalidomide also was granted the designation for treatment of anemia, due to myelodysplastic syndromes (MDS (nyse: MDZ - news - people )), which refers to

Cancer expert goes to source  -  Feb 5, 2008
Las Vegas Review - Journal,Already, in mice, Ma has found that it is present in myelodysplastic syndromes, or MDS, a group of diseases in which the bone marrow doesn't produce enough

Celgene Reports Record Fourth Quarter and Full Year 2007 Product ...  -  Jan 31, 2008
StreetInsider.com (subscription),Placebo in Patients Previously Treated for Multiple Myeloma -- Clinical Data From REVLIMID Study In Myelodysplastic Syndromes Reported In the Journal

German Regulators OK Celgene’s Acquisition of Pharmion  -  Feb 5, 2008
FDA news (subscription),Vidaza (azacitidine) is approved in the US for myelodysplastic syndromes and has demonstrated unprecedented overall survival benefit in a Phase III trial.

New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R ...  -  Feb 1, 2008
FOXBusiness...invasive fungal infections (IFIs) due to Aspergillus in neutropenic patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML),

Cytokinetics, Incorporated Reports Fourth Quarter and Year End ...  -  Feb 1, 2008
FOXBusiness...cycle to adult patients with relapsed or refractory acute leukemias, chronic myelogenous leukemia in blast crisis or advanced myelodysplastic syndromes.

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year  -  Feb 13, 2008
PR Newswire (press release),Genzyme is developing the product for use globally as a first-line therapy for the treatment of adult acute myeloid leukemia and myelodysplastic syndromes,

Cimarex Energy Posts 7% Rise In Q4 Oil And Gas Production Volumes ...  -  Feb 7, 2008
RTT News,Vidaza is a drug to be used in patients with higher-risk myelodysplastic syndromes (MDS). The company also stated its intention to review the application

Celgene Gets Split Decision on International Revlimid Applications  -  Feb 1, 2008
FDA news (subscription),The Canadian Therapeutic Products Directorate granted Revlimid conditional marketing approval for anemia from deletion 5Q myelodysplastic syndromes (MDS)

Observational Data Show Transfusion Patterns in Chemotherapy ...  -  Feb 1, 2008
PR Newswire (press release),...known history of a seizure disorder or underlying hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders).

Celgene Paints Promising Picture At Wachovia Healthcare Conference  -  Feb 1, 2008
Cafepharma,It was approved for myelodysplastic syndromes (MDS) and multiple myeloma (MM) in Australia. Canada also approved Revlimid for MDS.

Market Report -- In Play (SGP)  -  Jan 31, 2008
MSN Money...for prophylaxis of invasive fungal infections due to Aspergillus in neutropenic patients with myelodysplastic syndromes or acute myelogenous leukemia,

Celgene Says REVLIMID Receives Conditional Marketing Authorisation ...  -  Jan 24, 2008
Trading Markets (press release),...actions regarding REVLIMID in Australia in multiple myeloma or MM, and in Canada and the European Union in deletion 5q myelodysplastic syndromes or MDS.

Search the web for more resources on

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.